Age alone is not a treatment indication
Cannabinoids are studied in older adults for particular clinical problems, not as a general remedy for ageing. The meaningful question is whether a defined preparation improves a symptom while preserving the person’s ability to function. Pain, agitation, sleep and independence are related concerns, but improvement in one does not automatically establish improvement in the others.
That distinction is especially important when somebody already takes several medicines or needs help with everyday activities. A treatment can change how a symptom is reported while also changing alertness, mobility or the burden of care.
A small Alzheimer’s trial produced a specific result
A 2019 randomised crossover trial studied nabilone, a synthetic cannabinoid, in 39 people with moderate-to-severe Alzheimer’s disease and agitation. Their mean age was 87. Agitation scores favoured nabilone over placebo, with a four-point difference on the Cohen-Mansfield Agitation Inventory in the analysis.
Sedation occurred during 45% of nabilone phases versus 16% of placebo phases. Cognitive measures did not give a uniformly favourable result. This is a signal about a particular medicine and symptom, accompanied by an important trade-off; it is not evidence that cannabis reverses dementia. The trial’s small size also limits how confidently the result can be generalised.
Daily function is a separate outcome
A prospective observational study published in 2023 followed older adults beginning medical cannabis, mostly for chronic non-cancer pain. After six months, basic activities-of-daily-living scores did not significantly change; instrumental activities scores improved statistically. The authors nevertheless reported serious adverse events in the cohort.
Because this was an observational study, the change cannot isolate cannabis from other influences on care and health. Its useful contribution is the outcome it examines: whether people maintain functions such as managing everyday tasks. Symptom scores alone cannot answer that question.
Why balance and other medicines matter
Health Canada identifies several effects particularly relevant to later life. THC can impair attention and coordination, and cannabis can lower blood pressure when a person stands up. Dizziness and poor balance can therefore combine rather than remain separate inconveniences.
Age-related changes, existing illness and concurrent medicines also affect the response. Sedating medicines or alcohol can add to functional impairment, while other interactions can alter drug effects. For an older person, preserving safe movement and clear thinking can be as important as reducing the target symptom. A calmer appearance is not automatically evidence of better wellbeing.
A clinical goal needs more than a positive impression
Useful clinical outcomes are concrete: less distress, a meaningful change in pain, maintained mobility, or better ability to complete ordinary activities. They can be assessed alongside alertness, falls and changes in existing treatment. This makes the benefit-risk balance specific to the person and the preparation rather than to the word cannabis.
Spain’s Royal Decree 903/2025 establishes a regulated framework for standardised cannabis preparations used in magistral formulations. That clinical framework is distinct from association membership or an unregulated wellness product. Research in older adults supports careful symptom-specific evaluation, not a general promise of rejuvenation.
Sources & further reading
General information, not individual legal or medical advice.